anti cd25 mab (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
95
Structured Review
Bio X Cell
anti cd25 mab
Anti Cd25 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 179 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd25+mab/InVivoMAb+anti-mouse+CD25/pmc13022483-359-7-16
Average 95 stars, based on 179 article reviews
Anti Cd25 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 179 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd25+mab/InVivoMAb+anti-mouse+CD25/pmc13022483-359-7-16
Average 95 stars, based on 179 article reviews
anti cd25 mab - by Bioz Stars,
2026-09
95/100 stars
Images
1) Product Images from "CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine"
Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine
Journal: Communications Biology
doi: 10.1038/s42003-026-09721-9
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with G1: PBS, G2: 100 μg PMO, G3: 200 μg anti-CD25 mAb, G4: vaccine (10 μg Antigen/100 μg PMO 1:10), G5: 200 μg anti-CD25 mAb and vaccine (10 μg Antigen/100 μg PMO 1:10). Blood collection was performed 2 weeks after each immunization. Mice were sacrificed three weeks after the third immunization for draining lymph node analysis. B RBD-specific IgG titers of BALB/c mice serum at 2, 5, 8 and IgG1 OD 450 at 8 weeks. ( C ) Geometric mean neutralizing antibody titers (ID50) against WT (D614G), B1.1.7, B.1.617.2, BA.1, BA.2, and BA.2.75 at 8 weeks post-immunization. Pre-immune sera were evaluated to confirm that there were no non-specific effects on viral entry. B , C Error bars in the figure indicate geometric mean. Data are represented as geometric means ± geometric SEM. D B cells gating strategy; B cells (CD3 − B220 + ), GC B cells (CD3 − B220 + IgD − GL-7 + ), Plasma (B220 − CD138 + ), Memory B cells (CD3 − B220 + IgD − GL-7 − CD138 − CD38 + ). E B cells in live cells percentages. F GC B cells in B cells representative flow cytometry and percentages. G RBD-specific GC B cells in GC B cells percentages and absolute counts per million. H Absolute Treg cells counts per million. I Tfh cells in CD4 + T percentages and absolute counts per million. J Tfr cells in CD4 + T percentages and absolute counts per million. K Tfh:Tfr representative flow cytometry and ratio. L Schematic diagram. All error bars in the figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Techniques Used: Injection, Clinical Proteomics, Flow Cytometry
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with G1: 10 μg RBD antigen, G2: 10 μg RBD antigen and 200 μg anti-CD25 mAb, G3: vaccine (Antigen/zAS03 10 μg: 50 μl), G4: vaccine (Antigen/zAS03 10 μg: 50 μl) and 200 μg anti-CD25 mAb, G5: vaccine (Antigen/Alum 10 μg:100 μg), G6: vaccine (Antigen/Alum 10 μg:100 μg) and 200 μg anti-CD25 mAb. Mice were sacrificed at 14 days post-immunization for draining lymph node analysis. B GC B cells in B cells percentages and absolute counts per million. C RBD-specific GC B cells in GC B percentages and absolute counts per million. D GC B cells in B cells and RBD-specific GC B cells in GC B cells representative flow cytometry. E Tfh cells in CD4 + T percentages and absolute counts per million. F RBD-specific Tfh cells in Tfh cells percentages and absolute counts per million. All error bars in figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Techniques Used: Injection, Flow Cytometry
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with 200 μg anti-CD25 mAb and vaccine (Antigen/PMO 10 μg:100 μg). Mice were sacrificed at 1, 3-, 6-, 9- and 12-days post-immunization for draining lymph node analysis. B B cells and CD4 + T in live cells percentages change over time. C The absolute counts per million of CD25 + CD4 + T cells (Treg), CD25 + B cells and CD25 + CD8 + T cells change over time. D Schematic diagram. E The absolute counts per million of Breg and non Breg IL-10 cells change over time and representative flow cytometry. F The absolute counts per million of GC B cells and RBD-specific GC B cells change over time. G The absolute counts per million of Tfh cells change over time. H Schematic diagram. All error bars in figures indicate SEM. Data are represented as means ± SEM. All P values are from repeated-measures ANOVA with Mauchly’s test assessed. Greenhouse–Geisser correction was applied when needed. Post hoc comparisons used Šidák adjustment.
Techniques Used: Injection, Flow Cytometry
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with 200 μg anti-CD25 mAb at different time points before and after injection with vaccine (Antigen/PMO 10 μg:100 μg). Mice were sacrificed at 14 days post-immunization for draining lymph node analysis. B Treg cells in CD4 + T percentages and absolute counts per million. C GC B cells in B cells percentages and absolute counts per million. D GC B cells in B cells percentages representative flow cytometry. E Tfh cells in CD4 + T percentages and absolute counts per million. F Tfr cells in CD4 + T percentages and absolute counts per million. G Tfh:Tfr representative flow cytometry and ratio. All error bars in the figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Techniques Used: Injection, Flow Cytometry
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with G1: vaccine (Antigen/PMO 10 μg:100 μg), G2 and G3: 200 μg anti-CD25 mAb and vaccine (Antigen/PMO 10 μg:100 μg). Blood collection was performed 2 weeks after each immunization ( n = 7). Mice were sacrificed three weeks after the third immunization for draining lymph node and spleen analysis ( n = 4). B RBD-specific IgG titers of BALB/c mice serum at 2, 5, 8 ( n = 7) and 13 weeks ( n = 3). Error bars in the figure indicate geometric mean. C Geometric mean neutralizing antibody titers (ID50) against WT (D614G), B1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.4/5, and BA.2.75 at 8 weeks post-immunization. Pre-immune sera were evaluated to confirm that there were no non-specific effects on viral entry ( n = 7). B , C Error bars in the figure indicate geometric mean. Data are represented as geometric means ± geometric SEM. D B cells in live cells percentages. E GC B cells in B cells and RBD-specific GC B cells in GC B cells representative flow cytometry, percentages, and absolute counts per million. F Plasma absolute counts per million. G Treg absolute counts per million. H Tfh and Tfr cells in CD4 + T percentages and absolute counts per million. I Schematic diagram. J The frequencies of CD69 + IFN-γ + in CD4 + T and CD8 + T cells. K Representative figures and quantification of ELISPOT. All error bars in the figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Techniques Used: Injection, Flow Cytometry, Clinical Proteomics, Enzyme-linked Immunospot
Figure Legend Snippet: A BALB/c mice received bilateral subcutaneous injection with G1: vaccine (Antigen/PMO 10 μg:100 μg), G2 and G3: 200 μg anti-CD25 mAb and vaccine (Antigen/PMO 10 μg:100 μg). Blood collection was performed 2 weeks after each immunization ( n = 7). Mice were sacrificed three weeks after the third immunization for draining lymph node and spleen analysis ( n = 4). B RBD-specific IgG titers of BALB/c mice serum at 2, 5, 8 ( n = 7) and 13 weeks ( n = 3). C Geometric mean neutralizing antibody titers (ID50) against WT (D614G), B1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.4/5, and BA.2.75 at 8 weeks post-immunization. Pre-immune sera were evaluated to confirm that there were no non-specific effects on viral entry ( n = 7). B , C Error bars in the figure indicate geometric mean. Data are represented as geometric means ± geometric SEM. D VOC strains ID50 value/WT (D614G) strain ID50 value ratio for each individual mouse. E Serum neutralizing breadth against multiple viruses (Breadth reflect % strains neutralized per mouse at serum). F B cells in live cells percentages. G GC B cells in B cells and RBD-specific GC B cells in GC B cells representative flow cytometry, percentages, and absolute counts per million. H Plasma absolute counts per million. I Treg absolute counts per million. J Tfh and Tfr cells in CD4 + T percentages and absolute counts per million. All error bars in figures indicate SEM. Data are represented as means ± SEM. All P values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Techniques Used: Injection, Flow Cytometry, Clinical Proteomics
Figure Legend Snippet: Anti-CD25 induces rapid depletion of suppressive Tregs and Bregs, dismantling immunosuppressive checkpoints that constrain T cell priming and B cell activation. This establishes an immunostimulatory niche within hours to days of vaccination. By depleting these regulatory cells, anti-CD25 kinetically reshapes GC dynamics, it accelerates GC initiation, sustains quantitative amplification of total GC B cells through nonspecific expansion, and elevates the Tfh:Tfr ratio to license enhanced T-B collaboration. Crucially, while antigen-specific frequency within GC B cells remains unchanged, absolute numbers of antigen-specific effectors rise proportionally to total GC expansion. Functionally, this strategy broadens neutralizing antibody responses against both conserved and mutated epitopes, delivers timing-dependent enhancement of cellular immunity, and operates in an adjuvant-agnostic manner. Collectively, anti-CD25 leverages regulatory cell depletion to license early, sustained GC reactions—quantitatively amplifying antigen-specific immunity without altering clonal selection stringency.
Techniques Used: Activation Assay, Amplification, Adjuvant, Selection
Related Articles
Injection:Article Title: Aire is not essential for regulating neuroinflammatory disease in mice transgenic for human autoimmune-diseases associated MHC class II genes HLA-DR2b and HLA-DR4 Article Snippet: .. Aire −/− and Aire +/+ HLA-DR4 tg mice were injected i.p. with 800 μg of anti-CTLA-4 mAb (Bio X cell; UC10-4F10) and Aire −/− and Aire +/+ HLA-DR2b tg mice were given i.p a combination of 100 μg of anti-CTLA-4 mAb and 1 mg of Article Title: MiR‐192‐5p/RB1/NF‐κBp65 signaling axis promotes IL‐10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment Article Snippet: MiR‐192‐5p antagomir/NC (RiboBio, # miR30000517‐4‐5, China) was injected into the tumour at a dose of 5 nmol/50 μl PBS on day 10, 15 and 20. .. Article Title: Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment Article Snippet: CD8, CD4 T cells and NK cells (in C57BL/6) were depleted in vivo by i.p. injection of 250 μg/mouse of 2.43, GK1.5, or PK136 mAb (BioXCell) respectively, twice a week for 2 to 3 weeks. .. For T reg depletion, mice were injected i.p. with a single dose of 400 μg/mouse of Article Title: IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice Article Snippet: 0.6 mg of a blocking anti-IL6 mAb (clone MP5-20F3, BioXcell) were injected i.v. on day −1 and 0.3 mg on days 4 and 6. (Fig. ). .. Indicated groups of cardiac allograft recipients treated with ATG/CTLA4-Ig + αIL6 were injected with a depleting Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine Article Snippet: The aluminum adjuvant was purchased from InvivoGen (vac-alu-50, San Diego, CA, USA). zAS03 is a squalene-based oil-in-water emulsion adjuvant, generously provided by Professor Zhang Yong at the National Engineering Laboratory for AIDS Vaccine, Jilin University . .. To investigate the early-stage immune response to Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine. Article Snippet: The aluminum adjuvant was purchased from InvivoGen (vac-alu-50, San Diego, CA, USA). zAS03 is a squalene-based oil-in-water emulsion adjuvant, generously provided by Professor Zhang Yong at the National Engineering Laboratory for AIDS Vaccine, Jilin University42. .. Immunization of mice and sample collection To investigate the early-stage immune response to Transplantation Assay:Article Title: IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice Article Snippet: 0.6 mg of a blocking anti-IL6 mAb (clone MP5-20F3, BioXcell) were injected i.v. on day −1 and 0.3 mg on days 4 and 6. (Fig. ). .. Indicated groups of cardiac allograft recipients treated with ATG/CTLA4-Ig + αIL6 were injected with a depleting Flow Cytometry:Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine Article Snippet: The aluminum adjuvant was purchased from InvivoGen (vac-alu-50, San Diego, CA, USA). zAS03 is a squalene-based oil-in-water emulsion adjuvant, generously provided by Professor Zhang Yong at the National Engineering Laboratory for AIDS Vaccine, Jilin University . .. To investigate the early-stage immune response to Article Title: CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine. Article Snippet: The aluminum adjuvant was purchased from InvivoGen (vac-alu-50, San Diego, CA, USA). zAS03 is a squalene-based oil-in-water emulsion adjuvant, generously provided by Professor Zhang Yong at the National Engineering Laboratory for AIDS Vaccine, Jilin University42. .. Immunization of mice and sample collection To investigate the early-stage immune response to |
